Revolution Medicines Stock News

Morgan Stanley lifted its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 230.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 526,418 shares of the companys stock after purchasing an additional 367,073 shares during the period. Morgan Stanleys holdings in Revolution []

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) have received a consensus recommendation of Buy from the seven analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokers []

This move is a reversal from the hour prior, which saw price move up. The post Revolution Medicines Inc (RVMD): Price Down $-0.12 (-0.36)% Over Past Day, Down $-0.12 (-0.36)% Over Past Hour appeared first on ETF Daily News .

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q3 2021 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for

Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session

Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier

Revolution Medicines, Inc. (RVMD) CEO Dr. Mark Goldsmith on Q2 2021 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.09% and -19.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st

Shares of Revolution Medicines (NASDAQ:RVMD) fell 8.0% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 30.43% year over year to ($0.60), w

Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic

Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time

Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company's First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor Findings Published in Nature Chemi

Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies